KUALA LUMPUR (Aug 26): TMC Life Sciences Bhd (KL:TMCLIFE) returned to the black in its fourth financial quarter, reversing two straight quarters of losses linked to terminated contracts with insurers. The recovery was underpinned by stronger topline growth.

The group reported a net profit of RM2.42 million for the quarter ended June 30, 2025 (4QFY2025), more than double the RM1.02 million posted a year earlier.

Revenue rose 25.8% to RM93.27 million from RM74.12 million, driven by higher patient volumes at its Oncology Centre and reduced corporate discounts at Thomson Hospital Kota Damansara, according to the group's filing with Bursa Malaysia.

For the full year, TMC's net profit plunged 91.1% to RM3.61 million from RM40.65 million in FY2024, while revenue slipped marginally by 0.3% to RM345.54 million from RM346.42 million.

The group declared a final dividend of 0.1863 sen per share for FY2025, lower than the previous year’s full-year payout of 2.2169 sen, which included a special dividend of 1.7271 sen.

Looking ahead, TMC flagged potential cost pressures and supply chain risks stemming from rising tariffs and trade restrictions. It said it is actively monitoring developments and will continue to implement mitigating measures to safeguard operational resilience and business continuity.

Despite external challenges, the group remains upbeat on growth prospects, citing increased capacity at Thomson Hospital Kota Damansara and the ongoing expansion of its oncology centre as key drivers. The group is also accelerating efforts in medical tourism and onboarding new corporate clients to diversify its revenue streams.

TMC also said it will continue executing strategic initiatives focused on operational efficiency, customer acquisition and profitability enhancement through cost optimisation and service innovation.

Shares in TMC Life were up 2.5 sen or 6.2% at 43 sen on Tuesday, valuing the group at RM749 million. Year-to-date, the stock has declined 14%.